Behrouz Zand, MD
Gynecologic Oncology · The Woodlands, TXNPI 1619286465
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (51.5%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 28 manufacturers reported payments, led by Merck at 49.2% of the total. Reporting peaked in 2024 at $5,037 and has fallen 61.9% since, to $1,917 in 2025.
Across 102 payments — averaging $101.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$5K
- Karyopharm Therapeutics Inc.$929
- Medtronic$558
- Myriad Genetic Laboratories, Inc.$553
- Tempus AI, Inc$491
- Baxter Healthcare$468
- plus $2K from 22 others
What the payments were for
- Consulting fees$5,31251%
- Travel & lodging$1,26212%
- Food & beverage$3,74736%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 14 | $5,079 |
| Karyopharm Therapeutics Inc. | 3 | $929 |
| Medtronic | 2 | $558 |
| Myriad Genetic Laboratories, Inc. | 7 | $553 |
| Tempus AI, Inc | 14 | $491 |
| Baxter Healthcare | 4 | $468 |
| Stryker | 1 | $435 |
| GSK | 15 | $351 |
| AstraZeneca | 8 | $276 |
| Dilon Technologies, Inc. | 1 | $174 |
| AbbVie | 3 | $166 |
| Davol Inc. | 1 | $162 |
| Johnson & Johnson(2 entities) | 6 | $142 |
| Genmab U.S., Inc. | 3 | $71 |
| Mimedx Group, Inc. | 1 | $63 |
| Eisai Inc. | 3 | $58 |
| Daiichi Sankyo Inc. | 2 | $49 |
| Incyte Corporation | 2 | $44 |
| Meditrina | 2 | $44 |
| Integra Lifesciences Corporation | 2 | $38 |
| Aroa Biosurgery Incorporated | 1 | $32 |
| Bayer | 1 | $23 |
| Immunogen, Inc. | 1 | $22 |
| Evofem Biosciences, Inc. | 1 | $20 |
| Pfizer | 1 | $19 |
| Exact Sciences | 1 | $19 |
| Coopersurgical, Inc. | 1 | $18 |
| Astellas Pharma US Inc | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XPOVIO$929
- PreciseTumor$441
- 1688$435
- PerClot$289
- HemoBlast Bellows$174
- ARISTA AH FLEXITIP$162
- SEPRAFILM$132
- Elahere$125
- LYNPARZA$125
- ZEJULA$112
How this compares
$10,321 in reported general payments places this provider in the 70th percentile of 135 gynecologic oncology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ondansetron Hcl | 11 | $123 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 17 | $91 |
| Gabapentin | 11 | $41 |
Paid to pharmacies, not to this prescriber.
Other gynecologic oncology in The Woodlands
- Richard DrakeThe Woodlands$25K
- Robert ColemanHouston$864K
- Reagan StreetFort Worth$280K
- Joseph de la GarzaSan Antonio$234K
- Maurie MarkmanHouston$204K
- Dustin MandersDallas$171K
- Tiffany RedfernFort Worth$165K
- Antonio Santillan-GomezSan Antonio$162K
- Michael FrumovitzHouston$156K
- Eugene ToyEl Paso$138K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.